family with sequence similarity 47 member AGenealiases: []
Q-omics provides the consensus-scored FAM47A profile across patient tissues and cancer cell-line models. FAM47A expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FAM47A is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, FAM47A RNA expression shows 13,558 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where FAM47A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM47A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM47A survival associations across molecular data types. FAM47A RNA expression shows survival associations in the most cancer types (14), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM47A RNA expression–survival associations across cancer types. High FAM47A expression shows unfavorable associations in LIHC, CESC, STAD and SCLC, but favorable associations in LUSC and UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FAM47A RNA expression.
This table summarizes FAM47A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM47A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM47A shows lower tumor expression in KIRC and higher tumor expression in HNSC, BRCA, LUAD and LUSC. The HNSC box plot shows higher FAM47A RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p = .001).
This table shows molecular features associated with FAM47A in patient tissues and cancer cell lines. In patient samples, FAM47A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM47A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
